A detailed history of Jane Street Group, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 66,512 shares of BMRN stock, worth $4.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,512
Previous 209,292 68.22%
Holding current value
$4.22 Million
Previous $17.2 Million 72.87%
% of portfolio
0.0%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $9.85 Million - $13.4 Million
-142,780 Reduced 68.22%
66,512 $4.68 Million
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $5.94 Million - $7.36 Million
-79,818 Reduced 27.61%
209,292 $17.2 Million
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $8.93 Million - $10.6 Million
106,578 Added 58.39%
289,110 $25.3 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $4.41 Million - $5.7 Million
57,878 Added 46.43%
182,532 $17.6 Million
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $6.44 Million - $7.15 Million
-75,714 Reduced 37.79%
124,654 $11 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $11.6 Million - $13.4 Million
134,089 Added 202.31%
200,368 $17.4 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $857,921 - $1.15 Million
-9,778 Reduced 12.86%
66,279 $6.44 Million
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $3.73 Million - $5.01 Million
46,087 Added 153.78%
76,057 $7.87 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $1.26 Million - $1.48 Million
15,313 Added 104.48%
29,970 $2.54 Million
Q2 2022

Aug 16, 2022

SELL
$71.48 - $86.85 $5.37 Million - $6.52 Million
-75,117 Reduced 83.67%
14,657 $1.22 Million
Q1 2022

May 17, 2022

BUY
$74.28 - $92.69 $4.9 Million - $6.12 Million
65,995 Added 277.53%
89,774 $6.92 Million
Q4 2021

Feb 15, 2022

SELL
$71.72 - $91.47 $1.46 Million - $1.86 Million
-20,333 Reduced 46.09%
23,779 $2.1 Million
Q3 2021

Nov 16, 2021

SELL
$74.77 - $85.47 $2.34 Million - $2.68 Million
-31,312 Reduced 41.51%
44,112 $3.41 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $1.75 Million - $1.96 Million
23,174 Added 44.35%
75,424 $6.29 Million
Q1 2021

May 18, 2021

SELL
$74.73 - $90.69 $8.44 Million - $10.2 Million
-112,986 Reduced 68.38%
52,250 $3.95 Million
Q4 2020

Feb 17, 2021

SELL
$72.61 - $90.2 $1.95 Million - $2.43 Million
-26,907 Reduced 14.0%
165,236 $14.5 Million
Q3 2020

Nov 17, 2020

BUY
$71.87 - $131.03 $12.9 Million - $23.5 Million
179,452 Added 1414.01%
192,143 $14.6 Million
Q2 2020

Aug 17, 2020

SELL
$79.55 - $124.22 $2.33 Million - $3.63 Million
-29,262 Reduced 69.75%
12,691 $1.57 Million
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $1.73 Million - $2.35 Million
24,235 Added 136.78%
41,953 $3.55 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $272,504 - $366,208
4,240 Added 31.46%
17,718 $1.5 Million
Q3 2019

Nov 14, 2019

SELL
$67.4 - $85.11 $664,227 - $838,759
-9,855 Reduced 42.24%
13,478 $908,000
Q2 2019

Aug 15, 2019

BUY
$80.35 - $93.9 $716,159 - $836,930
8,913 Added 61.81%
23,333 $2 Million
Q1 2019

May 16, 2019

SELL
$84.2 - $98.62 $1.88 Million - $2.2 Million
-22,278 Reduced 60.71%
14,420 $1.28 Million
Q4 2018

Feb 15, 2019

SELL
$80.14 - $106.07 $3.2 Million - $4.24 Million
-39,958 Reduced 52.13%
36,698 $3.13 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $5.97 Million - $6.72 Million
63,551 Added 484.94%
76,656 $7.43 Million
Q2 2018

Aug 15, 2018

SELL
$76.01 - $99.03 $244,220 - $318,183
-3,213 Reduced 19.69%
13,105 $1.23 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $277,048 - $330,411
3,567 Added 27.97%
16,318 $1.32 Million
Q4 2017

Feb 15, 2018

BUY
$80.76 - $95.13 $1.03 Million - $1.21 Million
12,751
12,751 $1.14 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.